You are here: Home » News-ANI » Health
Business Standard

Oral steroids increases risk of infection in patients with inflammatory disease

Health Medical Pharma


Usage of oral steroid in patients with inflammatory diseases like polymyalgia rheumatica or giant cell arteritis significantly increased the risk of infection and the risk increases with higher doses.

The study was published in the 'CMAJ' (Canadian Medical Association Journal).

In a large study of almost 40, 000 adult patients with polymyalgia rheumatica or giant cell arteritis in England, researchers found higher absolute risks of infection when patients were taking oral steroids than when they were not taking them.

The mean age of patients in the study was 73 years. Steroids included prednisolone, prednisone, hydrocortisone, and cortisone. The risk of infection increased with higher doses and was elevated even with low daily doses of less than 5 mg of prednisolone.

"In periods with prescribed medication, patients' risk was 50 per cent higher than when it was not prescribed," wrote Dr Mar Pujades-Rodriguez, Leeds Institute of Data Analytics, University of Leeds.

"Increases in risk ranged from 48 per cent for fungal to 70 per cent for bacterial infections," added Dr Pujades-Rodriguez.

More than half of patients (22 234, 56 per cent) had infections with the most common infections being lower respiratory tract infections (27 per cent), conjunctivitis (9 per cent) and shingles (7 per cent). More than one-quarter (27 per cent) of patients were admitted to hospital and seven per cent died within a week of diagnosis of infection.

"Patients and clinicians should be educated about the risk of infection, need for symptom identification, prompt treatment, timely vaccination and documentation of the history of chronic infection (e.g. herpes zoster)," wrote the authors.

The authors suggested that estimates of dose-response (i.e., the magnitude of risk related to steroid dosing) can be useful for policy-makers in assessing new glucocorticoid-sparing drugs for patients with these inflammatory diseases.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Mon, June 24 2019. 17:13 IST